FAES FARMA, S.A. to the NATIONAL SECURITIES MARKET COMMISSION (CNMV) notifies the following:

OTHER RELEVANT INFORMATION

Faes Farma has received the new laboratory authorisation from the European Union including the new manufacturing plant in Derio (Bizkaia), together with its GMP (Good Manufacturing Practices) certificate from the Spanish Agency for Medicines and Health Products (AEMPS).

This certificate allows the manufacture of medicines in this new plant for the same pharmaceutical forms as in the current plant in Lamiako-Leioa-Bizkaia and additionally for liquid sticks and soft capsules.

Therefore, it is now possible to immediately start submitting the registration variations for each product, first in Spain/Europe and then in the rest of the countries, in order to start marketing the medicines manufactured at the new plant in Derio. As authorisations are received, production will be transferred in stages from one plant to the other.

The new plant is located in the Bizkaia Science and Technology Park and has around 60,000 square metres of floor space, of which the pharmaceutical production area occupies around 20,000 square metres.

The new plant will double the current industrial capacity of the Lamiako plant (Leioa) and will be able to produce more than 100 million units of medicines each year, thanks to the incorporation of new high-value technologies and operational excellence.

Leioa, 7 January 2025